Although several antiviral treatments for HBV infection have recently reached the market, no direct acting antiviral drugs to treat infection with HCV have been licensed in the 20 years since its identification. Excitingly, recent publications herald several small revolutions in antiviral treatment of HCV that have considerable relevance for prospective HCV therapies.
References
Manns, M. P. et al. The way forward in HCV treatment—finding the right path. Nat. Rev. Drug Discov. 6, 991–1000 (2007).
McHutchison, J. G. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292–1303 (2010).
Kwo, P. Y. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705–716 (2010).
Jacobson, I. M. et al. Telaprevir in combination with Peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study [abstract 211]. Hepatology 52 (Suppl.), 427A (2010).
Poordad, F. et al. Boceprevir (BOC) combined with Peginterferon alfa-2B/ribavirin for treatment-naive patients with hepatitis C virus (HCV) genotype 1 SPRINT-2 final results. Hepatology 52 (Suppl.), 107A (2010).
Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467–1475 (2010).
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577–1581 (2005).
Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198–201 (2010).
Patel, H. & Heathcote, E. J. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut doi:10.1136/gut.2010.217323.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. P. Manns has been a speaker for Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck and Roche. He has been a consultant for Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck, Novartis, Roche, Tibotec and Vertex. He has received grant/research support from Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Roche and Novartis.
Rights and permissions
About this article
Cite this article
Ciesek, S., Manns, M. The dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 8, 69–71 (2011). https://doi.org/10.1038/nrgastro.2010.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.219
- Springer Nature Limited
This article is cited by
-
Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data
Infectious Diseases and Therapy (2019)
-
Chronic hepatitis C infection–induced liver fibrogenesis is associated with M2 macrophage activation
Scientific Reports (2016)
-
Protocol for a systematic review and meta-analysis of hepatitis C virus (HCV) prevalence and incidence in the Horn of Africa sub-region of the Middle East and North Africa
Systematic Reviews (2014)
-
Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naïve and –experienced patients
BMC Gastroenterology (2013)
-
Progress towards a hepatitis C virus vaccine
Emerging Microbes & Infections (2013)